NCT01530594

Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 440 (actual)
• Sponsor: King Faisal Specialist Hospital & Research Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose dexamethasone (BLLD) for induction, in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Lenalidomide/Low dose Dex	Lenalidomide/Low dose Dex (LLD)
DRUG	Bortezomib/Lenalidomide/ Low dose Dex	Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
DRUG	Lenalidomide	Lenalidomide/Low dose Dex (LLD

Timeline

• Start date: 2009-01-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2012-02-10
• Last updated: 2016-02-25

Locations

1 site across 1 country: Saudi Arabia